Majewski Wojciech, Tabor Kamil, Prokop Elżbieta, Kulik Roland
Department of Radiotherapy, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland.
Doctoral Degree Programme to Medical University of Silesia, Faculty of Medicine and Division of Medical Dentistry in Zabrze, Poland.
Contemp Oncol (Pozn). 2014;18(4):285-9. doi: 10.5114/wo.2014.44097. Epub 2014 Jul 16.
The evaluation of quality of life during image-guided radiotherapy (IGRT) in patients with prostate cancer.
The study consisted of 180 prostate cancer patients treated with radical radiotherapy (IGRT). The patients were irradiated using conformal or dynamic techniques with 2 Gy fractionation doses to a total dose of 76 Gy. Patients in the high-risk group (41%) were also irradiated to the pelvic lymph nodes. Quality of life was assessed with EORTC questionnaires: general QLQ-C30 and prostate-specific module QLQ-PR25, which were filled in by patients before and upon completion of radiotherapy. A change of ≥ 10 points in a linearised scale (0-100) was considered clinically significant.
Global quality of life decreased slightly during radiotherapy (from 61 to 57 points), but from the clinical point of view, likewise most of the other quality of life parameters remained stable. In the general module (QLQ-C30) only diarrhoea changed in a clinically relevant way, i.e. by 10 points (from 10 to 20 points), which was mainly observed in patients with elective pelvic irradiation (increase of 18 points, from 10 to 28 points). In the prostate-specific module (QLQ-PR25) only urinary symptoms changed significantly, i.e. by 13 points (from 24 to 37 points).
The quality of life in patients with prostate cancer does not change in a clinically significant way during radiotherapy, which corroborates good treatment tolerance. Increased urinary symptoms and, in the case of pelvic irradiation, also increased diarrhoea have a negative impact on symptom-related quality of life.
评估前列腺癌患者在图像引导放射治疗（IGRT）期间的生活质量。
该研究纳入了180例接受根治性放射治疗（IGRT）的前列腺癌患者。患者采用适形或动态技术进行照射，分次剂量为2Gy，总剂量为76Gy。高危组（41%）的患者还接受了盆腔淋巴结照射。使用欧洲癌症研究与治疗组织（EORTC）问卷评估生活质量：通用问卷QLQ-C30和前列腺特异性模块问卷QLQ-PR25，患者在放疗前和放疗结束时填写。线性量表（0-100）中变化≥10分被认为具有临床意义。
放疗期间总体生活质量略有下降（从61分降至57分），但从临床角度看，其他大多数生活质量参数同样保持稳定。在通用模块（QLQ-C30）中，只有腹泻有临床相关变化，即变化了10分（从10分增至20分），这主要见于接受选择性盆腔照射的患者（从10分增至28分，增加了18分）。在前列腺特异性模块（QLQ-PR25）中，只有泌尿症状有显著变化，即变化了13分（从24分增至37分）。
前列腺癌患者在放疗期间生活质量无临床显著变化，这证实了良好的治疗耐受性。泌尿症状增加，以及在盆腔照射情况下腹泻增加，对与症状相关的生活质量有负面影响。
